Showing 42 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Injectable & long-acting PrEP

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

Editor's pick
ViiV Healthcare press release
4 May 2021
Injectable & long-acting HIV treatment

Top 5 stories on injectable HIV treatment and prevention from CROI 2021

News
23 March 2021
Injectable & long-acting HIV treatment

Injectable HIV medications must be practical and affordable, conference hears

News
15 March 2021
Finance & funding

To be cost-effective, injectable PrEP can only cost about $3000 more than US generic oral PrEP

News
15 March 2021
PrEP science

HPTN 083: Injectable PrEP can make breakthrough infections hard to detect

News
10 March 2021
Injectable & long-acting PrEP

Reformulated islatravir implant should provide PrEP for over a year

News
9 March 2021
Vaginal rings & topical PrEP

Products to prevent both pregnancy and HIV begin to emerge

News
2 February 2021
Injectable & long-acting PrEP

Once-a-month PrEP pill easily passes its first big test

News
27 January 2021
Injectable & long-acting PrEP

A triumph for injectable PrEP, but a sobering result for oral PrEP

News
27 January 2021
Antibody-based prevention

Antibody-based PrEP did not stop most types of HIV – but is still hailed as a ‘game changer’

News
27 January 2021
People & personal stories

Anthony Fauci: “I don’t do this because I’m a hero. I do it because it’s necessary.”

News
14 January 2021
Injectable & long-acting PrEP

What do we know about injectable PrEP?

About HIV
December 2020
Injectable & long-acting PrEP

'A shot can end the stigma': African women pin hopes on anti-HIV jab

Editor's pick
Reuters
3 December 2020
Injectable & long-acting PrEP

ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention

Editor's pick
ViiV press release
17 November 2020
Injectable & long-acting PrEP

Merck Launches Major Trial of Monthly Islatravir PrEP Pill for Women

Editor's pick
POZ
16 November 2020
Injectable & long-acting PrEP

Study of injectable PrEP reports the best efficacy seen yet for any form of PrEP in women

News
13 November 2020
Injectable & long-acting PrEP

Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women

Editor's pick
World Health Organization
10 November 2020
Pharmaceutical industry

GlaxoSmithKline's HIV PrEP challenge looms as ViiV's long-acting drug tops Gilead's Truvada in women

Editor's pick
FiercePharma
10 November 2020
Injectable & long-acting PrEP

HIV prevention injection hailed as a “major breakthrough” for women

Editor's pick
Spotlight
10 November 2020
Injectable & long-acting PrEP

ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women

Editor's pick
ViiV press release
9 November 2020
Injectable & long-acting HIV treatment

Similar benefits and barriers to injectables for HIV prevention and treatment reported by US women

News
21 October 2020
Injectable & long-acting PrEP

Injectable PrEP offers superior efficacy to oral PrEP in clinical trial

News
7 July 2020
Injectable & long-acting HIV treatment

Injectable antiretrovirals for HIV treatment or prevention: ambivalent views of potential users

News
26 May 2020
Injectable & long-acting PrEP

Seventy per cent fewer HIV infections seen with PrEP injections, compared with pills, in gay/bi men and trans women

News
18 May 2020